Regeneron Pharma: European Commission approves Ordspono

BRUSSELS/FRANKFURT/PARIS (dpa-AFX) – Regeneron Pharmaceuticals, Inc. (REGN) announced that the European Commission has approved Ordspono or odronextamab for the treatment of adult patients with relapsed or refractory follicular lymphoma or R/R diffuse large B-cell lymphoma, after two or more lines of systemic therapy. This marks the first regulatory approval of Ordspono. Ordspono is a bispecific antibody that works by coupling the lymphoma cell to a killer T cell.

The company said the approval is based on results from the Phase 1 ELM-1 and pivotal Phase 2 ELM-2 studies, which demonstrated robust, durable response rates in adults with R/R FL or R/R DLBCL.

Visit rttnews.com for more health news.

Copyright(c) 2024 RTTNews.com. All rights reserved.

Copyright RTT News/dpa-AFX